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18 days in 2 patients who received 1 x 106/kg haplo-CD34+
cells. Platelet recovery occurred in 13/16 patients (median 26
days, range 17-46). While day 14 myeloid recovery was
predominantly haplo-mediated, one CB unit dominated by
day 28 in both neutrophil & T-cell subsets (Table). By day 60,
the median total donor chimerism was 100% the dominant
CB unit. With a median survivor follow-up of 7 months
(range 3-12),12/16 patients developed gr. II-IV aGVHD by day
100 (10 gr. II, 1 gr. III, 1 gr. IV). One refractory leukemia patient
relapsed & 5 had TRM (3 organ failure, 1 grade IV aGVHD, 1
CMV infection). Surviving patients were discharged at a 33
day median (9 days faster than DCBT controls).
Conclusions: Double-unit CBT with haplo-CD34+ cells is safe
& neutrophil engraftment is enhanced. A shorter initial
hospitalization offsets the haplo-CD34+ cell cost. It is
intriguing that the dominant CB unit can rapidly reject the
haplo-identical donor. Whether the same results could be
achievedwith single CB units, and whether myeloid recovery
could be further enhanced by a higher haplo-CD34+ cell
dose, require investigation.190
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
and CB can extend transplant access. We evaluated if URD/
CB access has improved with increased size of URD registries
& global CB inventories.
Methods: We prospectively collected ancestry data on
patients undergoing searches between 10/2005-6/2013, &
analyzed the availability of 9-10/10 HLA-matched URDs or
4-6/6 HLA-A,-B antigen, -DRB1 allele matched CB units by
recipient ancestry. 10 HLA-allele matched URDs were
given priority if available; otherwise HLA-mismatched
URDs or double-unit CB grafts were chosen. This analysis
was restricted to CB units with a cryo. TNC dose > 2.0.
Availability of CB units by 10-allele match was also
evaluated.Early Time Period
(n ¼ 424, 60% of total)
Recent Time Period
(n ¼ 284, 40% of total)
Europeans (n ¼ 485)
N ¼ 295 N ¼ 190
URD: 246 (71% 10/10) URD: 154 (76% 10/10)
CB: 42 (48%  6/10) CB: 35 (54%  6/10)
No graft: 7 (2%) No graft: 1 (0.5%)
Non-Europeans (n ¼ 223)
N ¼ 129 N ¼ 94
URD: 61 (48% 10/10) URD: 50 (56% 10/10)
CB: 46 (28%  6/10) CB: 36 (69%  6/10)
No graft: 22 (17%) No graft: 8 (8.5%)Results: Of 708 patients, 223 (31%) were non-European. URD
recipients were predominantly European (400/511, 78%)
whereas only 77/159 (48%) of CB recipients had European
origins. 30/38 (79%) “no graft” patients were non-European
(including 20 African ancestry patients), and they had a
higher weight (median 93 kg) than CB recipients, p < 0.001.
Graft availability during early (10/2005-12/2010) vs recent
(1/2011-6/2013) periods is shown (Table). Ancestry distri-
bution was equal during the periods. Of all early vs late
period patients, less than two-thirds of Europeans received a
10/10 URD in both eras (59% vs 61%) but very few had no graft
(< 1% recently). However, of non-Europeans in the early
period overall, only 29/129 (22%) had a 10/10 URD, & this has
not improved [28/94 (30%), p¼ 0.28]. While only 28% of non-
Europeans received  6/10 CB units in the early period, this
match rate improved to 69% recently (p < 0.001). The per-
centage of non-Europeans with no graft has decreased from
17% to 8.5% recently (p ¼ 0.08). Of African patients without
an URD, 16/31 (52%) had a CB graft in the early period vs 15/
20 (75%) recently, p ¼ 0.14.
Conclusion: Less than two-thirds of Europeans have a 10/10
URD, but very few do not have an URD &/or CB graft. CB,
unlike URDs, is a critically important donor source for mi-
norities, & transplantation of CB units with higher rates of 10
HLA-allele match is possible. Improved CB availability in
non-Europeans is suggested but an enlarged inventory is
required to extend access, especially for African ancestry
patients.191
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The Killer immunoglobulin-like receptor (KIR) genetic
system is polygenic and highly polymorphic. Several studies
conﬁrmed the KIR haplotype associationwith hematopoietic
stem cell transplant (HSCT) outcome, however, KIR haplo-
type assignment using KIR genotypes, is still a challenge even
with family information available, because KIR haplotypes
may vary in gene copy-number, gene content and allelic
diversity.
The goal of the present study is to assign KIR haplotypes in
related HSCT patient-donor pairs using next generation
sequencing (NGS) method.
We selected 10 families (n¼38 in total): 6 with both parents
available. All of them were previously typed with SSP-
Multiplex for KIR genotyping and Sequencing for 3DL1/2/3
alleles. Scisco KIR NGS method can distinguish KIR geno-
types, calculate gene copy number, estimate gene-content
haplotypes and assign KIR alleles.
KIR genotypes obtained with two methods:SSP and NGS
were identical. We are able to distinguish KIR haplotype
distribution within families. KIR gene copy number is
essential in this regard. However, if a sibling pair are both KIR
AA genotype, it is difﬁcult to distinguish KIR haplotype
matching, without KIR allele information. KIR allele assign-
ments are in progress.192
Impact of HLA Disparity with High-Resolution HLA
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Relative risk* of acute and chronic GVHD based on degree of high-resolution
HLA matching
Factor RR of aGVHD (95% CI) RR of cGVHD
(95% CI) (n¼79)
Grade II-IV
(n¼191)
Grade III-IV
(n¼72)
HLA match**
9-10/10 (n¼69) 1.0 1.0 1.0
6-8/10 (n¼246) 1.1 (0.7-1.8) 1.1 (0.5-2.5) 0.7 (0.3-1.5)
<6/10 (n¼89) 1.1 (0.7-2.0) 1.4 (0.6-3.3) 1.1 (0.1-2.5)
*Adjusted for age, gender match, year of transplant, number of units, CD3,
CD34 dose, ATG use, conditioning, recipient CMV status, prior aGVHD as
appropriate; **High-resolution allele match at HLA-A, -B, -C, -DRB1, and -DQ
loci; RR, relative risk; CI, conﬁdence interval
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Introduction: HLA-mismatched unrelated cord blood
transplantation (UCBT) is feasible and, in retrospective
comparative analyses, allows survival rates similar to con-
ventional unrelated HLA-matched adult-derived grafts. It is
clear that the degree of UCB HLA mismatch in patients has a
negative effect on outcomes with low-resolution HLA typing
at A, B, DR. But the impact of HLA disparity on outcomes with
high-resolution HLA typing HLA-A, -B, -C, -DR is unclear.
Patients and Methods: To determine the impact of HLA
disparity on outcomes after UCBT, We retrospectively
reviewed patients with hematologic malignancies who un-
derwent reduced intensity CBT at Toranomon Hospital from
August 2006 and December 2010 consecutively. Patients who
had prior history of transplantation,were inpoor performance
status (ECOGPS>3), had active bacterial or fungal infections at
the time of conditioning were excluded. The most frequently
used conditioning regimenswereﬂudarabine, alkylating agent
(melphalan or busulfan) with total body irradination (TBI),
tacrolimus plusmycophenolatemofetil for GVHD prophylaxis.
DNAs of 97 pairs were analysed for HLA-A, -B, -C, and -DRB1
basedonHighResolution typing. In these caseshigh resolution
typing was carried out retrospectively.
Results: For HLA-A, -B, -C, and -DR based on high resolution
typing the followingmismatch occurred: nomismatch 2(2%),
one mismatch 5(5%), twomismatch 14(14%), three mismatch
32(33%), four mismatch 28(29%), ﬁve mismatch 14(14%), six
mismatch 2(2%). The number of total nucleated cells and
CD34+ cells were not signiﬁcantly different among them.
The cumulative incidence of neutrophil recovery was
83.5% in this study population. It was higher in HLA-B
matched group than in HLA-B mismatched group ( 94.2% vs.
78.5% up to day 60, p¼0.0044), and in multivariate analysis
HLA-B mismatch was independent predictor of engraftment
(HR, 0.074; 95%CI, 0.0074-0.74; p¼0.026). Among the HLA-A,
-C, -DRB1 mismatches, the negative impact of each single
HLA allele mismatch was not signiﬁcant.
The cumulative incidence of grade II to IV aGVHD in this
study population was 52.6%. In multivariate analysis, HLA-A
mismatch (HR, 10.51; 95%CI, 1.95-56.51; p¼0.0061), and
HLA-B mismatch (HR, 51.59; 95%CI, 1.05-2520.0; p¼0.043)
were signiﬁcantly associated with high incidence of grade II-
IV GVHD.
There were no signiﬁcant difference in the cumulative
incidence of TRM, Relapse Rate and OS in this study.
Conclusion: HLA-B allele mismatch was found to have a
signiﬁcant negative impact on engraftment and II-IV aGVHD.193
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The degree of antigen-level (HLA-A, -B) and allele-level
HLA-DRB1 matching has been correlated with the risk of
acute GVHD (aGVHD) in prior studies of umbilical cord
blood transplantation (UCBT), however no impact of HLA
matching on development of chronic GVHD (cGVHD) has
been reported for 4/6-matched UCBT. To understand the
impact of high-resolution HLA allele matching at -A, -B, -C,
-DRB1 and -DQ loci on GVHD we studied 404 recipients of
single- (n¼129) and double-unit (n¼275, based on the
predominating unit) UCBT from 2000 to 2010. Overall cu-
mulative incidence of grade II-IV aGVHD, grade III-IV
aGVHD, and cGVHD was 47%, 18%, and 20%, respectively. HLA
allele-matched recipients, grouped as 9-10/10 (17%), 6-8/10
(61%), and <6/10 (22%), had a similar cumulative incidence
of grade II-IV (43% vs. 47% vs. 52%, p¼0.5) or grade III-IV
(17% vs. 16% vs. 22%, p¼0.4) aGVHD, respectively. In multi-
variable analysis HLA matching did not inﬂuence grade II-IV
and III-IV aGVHD (all p>0.5) after adjustment for the
number of units, CD3, CD34 dose, age, gender match, con-
ditioning, recipient CMV status, ATG use, and the year of
transplant (Table). Use of ATG was independently associated
with a lower risk of grade II-IV aGVHD (relative risk [RR]¼
0.5, p<0.01). Univariate difference in cumulative incidence
of cGVHD for 9-10/10 (17%), 6-8/10 (17%), and <6/10 (29%)
HLA match was confounded by age (RR¼3.4 for 18 years,
p<0.01) and prior aGVHD (RR¼2.3, p<0.01) in multivariable
analysis adjusted for CD34, CD3 dose, and the number of
cord units. No other factors inﬂuenced cGVHD or modiﬁed
the risk of HLA matching on cGVHD. Similar results were
found in a multivariable analysis for stratiﬁed single- and
double-unit UCBT. We conclude that stringent high-resolu-
tion HLA matching at -A, -B, -C, -DRB1 and -DQ loci does not
inﬂuence the incidence of acute or chronic GVHD among
recipients of UCBT.194
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